WO2010067374A2 - Polymorphs of dasatinib - Google Patents

Polymorphs of dasatinib Download PDF

Info

Publication number
WO2010067374A2
WO2010067374A2 PCT/IN2008/000822 IN2008000822W WO2010067374A2 WO 2010067374 A2 WO2010067374 A2 WO 2010067374A2 IN 2008000822 W IN2008000822 W IN 2008000822W WO 2010067374 A2 WO2010067374 A2 WO 2010067374A2
Authority
WO
WIPO (PCT)
Prior art keywords
dasatinib
solvate
solution
dimethylformamide
crystalline
Prior art date
Application number
PCT/IN2008/000822
Other languages
French (fr)
Other versions
WO2010067374A3 (en
Inventor
Bandi Parthasaradhi Reddy
Kura Rathnakar Reddy
Rapolu Raji Reddy
Dasari Muralidhara Reddy
Thungathurthy Srinivasa Roa
Original Assignee
Hetero Research Foundation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hetero Research Foundation filed Critical Hetero Research Foundation
Priority to PCT/IN2008/000822 priority Critical patent/WO2010067374A2/en
Publication of WO2010067374A2 publication Critical patent/WO2010067374A2/en
Publication of WO2010067374A3 publication Critical patent/WO2010067374A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Definitions

  • the present invention relates to novel polymorphs of dasatinib, processes for its preparation and to pharmaceutical compositions containing it.
  • Dasatinib are antineoplastic agents, which were disclosed in WO Patent Publication No. 00/62778 and U.S. Patent No. 6,596,746.
  • Dasatinib chemically N-(2-chloro-6-methylphenyl)-2-[[6-[4-(2-hydroxyethyl)-1-piperazinyl]-2-methyl-4- pyrimidinyl]amino]-5-thiazolecarboxamide, is represented by the following structure:
  • Polymorphism is defined as "the ability of a substance to exist as two or more crystalline phases that have different arrangement and /or conformations of the molecules in the crystal Lattice.
  • polymorphs are different crystalline forms of the same pure substance in which the molecules have different arrangements and / or different configurations of the molecules.
  • Different polymorphs may differ in their physical properties such as melting point, solubility, X-ray diffraction patterns, etc. Although those differences disappear once the compound is dissolved, they can appreciably influence pharmaceutically relevant properties of the solid form, such as handling properties, dissolution rate and stability. Such properties can significantly influence the processing, shelf life, and commercial acceptance of a polymorph.
  • Polymorphic forms of a compound can be distinguished in the laboratory by analytical methods such as X-ray diffraction (XRD), Differential Scanning Calorimetry (DSC) and Infrared spectrometry (IR).
  • XRD X-ray diffraction
  • DSC Differential Scanning Calorimetry
  • IR Infrared spectrometry
  • Solid solvent medium and mode of crystallization play very important role in obtaining a crystalline form over the other.
  • Dasatinib can exist in different polymorphic forms, which differ from each other in terms of stability, physical properties, spectral data and methods of preparation.
  • dasatinib monohydrate is characterized by an X-ray powder diffraction pattern having peaks expressed as 2 ⁇ at approximately 18.0, 18.4, 19.2, 19.6, 21.2, 24.5, 25.9 and 28.0 ⁇ 0.2 degrees.
  • dasatinb monohydrate can be obtained in dasatinib, by heating and dissolving the dasatinib in an ethanol and water mixture. Crystallizing the monohydrate from the ethanol and water mixture and cooled to get dasatinib monohydrate.
  • dasatinib crystalline butanol solvate is characterized by an X-ray powder diffraction pattern having peaks expressed as 2 ⁇ at approximately 5.9, 12.0, 13.0, 17.7, 24.1 and 24.6 ⁇ 0.2 degrees.
  • dasatinib crystalline ethanol solvate is characterized by an X-ray powder diffraction pattern having peaks expressed as 2 ⁇ at approximately 5.8, 11.3, 15.8, 17.2, 19.5, 24.1, 25.3 and 26.2 ⁇ 0.2 degrees.
  • dasatinib crystalline neat form (N-6) is characterized by an X-ray powder diffraction pattern having peaks expressed as 2 ⁇ at approximately 6.8, 11.1, 12.3, 13.2, 13.7, 16.7, 21.0, 24.3 and 24.8 ⁇ 0.2 degrees.
  • dasatinib crystalline neat form (T1H1-7) is characterized by an X-ray powder diffraction pattern having peaks expressed as 2 ⁇ at approximately 8.0, 9.7, 11.2, 13.3, 17.5, 18.9, 21.0 and 22.0 ⁇ 0.2 degrees.
  • U.S. Patent application No. 2006/0094728 disclosed ethanolate form (T1E2-1) of dasatinib, characterized by an X-ray powder diffraction pattern having peaks expressed as 2 ⁇ at approximately 7.2, 12.0, 12.8, 18.0, 19.3 and 25.2 ⁇ 0.2 degrees.
  • Another object of the present invention is to provide process for preparing the novel crystalline form of dasatinib, dasatinib dimethylformamide solvate, dasatinib dimethyl sulfoxide solvate, dasatinib toluene solvate, dasatinib isopropyl acetate solvate and known crystalline dasatinib monohydrate.
  • Still another object of the present invention is to provide pharmaceutical compositions containing the novel crystalline form of dasatinib.
  • dasatinib dimethyl formamide solvate characterized by peaks in the powder x- ray diffraction spectrum having 2 ⁇ angle positions at about 5.7, 11.5, 14.5, 17.3 and 25.1 ⁇ 0.2 degrees.
  • the powdered x-ray diffractogram (PXRD) of dasatinib dimethylformamide solvate is shown in figure 1.
  • a process for preparing dasatinib dimethylformamide solvate which comprises crystallizing dasatinib dimethylformamide solvate from a solution of dasatinib in N,N-dimethylformamide solvent.
  • N,N-dimethylformamide may alone be present as solvent in the solution or N,N-dimethylformamide in combination with water or any other solvent or solvents may be present.
  • N 1 N- dimethylformamide in combination with ethyl acetate or acetone may be present in the solution.
  • dasatinib dimethyl sulfoxide solvate characterized by peaks in the powder x-ray diffraction spectrum having 2 ⁇ angle positions at about 11.1, 15.1, 17.8, 19.0, 23.4 and 24.3 ⁇ 0.2 degrees.
  • the powdered x-ray diffractogram (PXRD) of dasatinib dimethyl sulfoxide solvate is shown in figure 2.
  • a process for preparing dasatinib dimethyl sulfoxide solvate which comprises crystallizing dasatinib dimethyl sulfoxide solvate from a solution of dasatinib in a solvent mixture comprising dimethyl sulfoxide and ethyl acetate.
  • dasatinib toluene solvate characterized by peaks in the powder x-ray diffraction spectrum having 2 ⁇ angle positions at about 5.8, 11.8, 15.3, 21.6 and 24.6 ⁇ 0.2 degrees.
  • the powdered x-ray diffractogram (PXRD) of dasatinib toluene solvate is shown in figure 3.
  • a process for preparing dasatinib toluene solvate which comprises crystallizing dasatinib toluene solvate from a solution of dasatinib in toluene.
  • dasatinib isopropyl acetate solvate characterized by peaks in the powder x-ray diffraction spectrum having 2 ⁇ angle positions at about 5.7, 6.0, 6.7, 12.2, 13.1, 17.1 and 21.8 ⁇ 0.2 degrees.
  • the powdered x-ray diffractogram (PXRD) of dasatinib isopropyl acetate solvate is shown in figure 4.
  • a process for preparing dasatinib isopropyl acetate solvate which comprises crystallizing dasatinib isopropyl acetate solvate from a solution of dasatinib in isopropyl acetate.
  • dasatinib form I The crystalline form designated as dasatinib form I, characterized by peaks in the powder x-ray diffraction spectrum having 2 ⁇ angle positions at about 7.1, 11.9, 12.2, 14.3, 16.4, 16.7, 19.0 and 24.1 ⁇ 0.2 degrees.
  • the powdered x-ray diffractogram (PXRD) of crystalline dasatinib form I is shown in figure 5.
  • the crystalline dasatinib form I may be identified and differentiated from the known polymorphs by its characteristic PXRD pattern. Thus, for example, a peak at 14.3 ⁇ 0.2 degrees 2 ⁇ is present in the PXRD of the crystalline dasatinib form I of the present invention, but is absent in the PXRD of the dasatinib crystalline neat form (N-6) disclosed in the US Patent Application No. 2005/0215795 Al
  • a process for preparation of crystalline dasatinib form I which comprises crystallizing dasatinib form I from a solution of dasatinib in a solvent mixture of ethyl acetate and methanol, or acetone and methanol.
  • a process for preparation of crystalline dasatinib monohydrate which comprises crystallizing dasatinib monohydrate from a solution of dasatinib dimethylformamide solvate in water.
  • a process for preparation of crystalline dasatinib monohydrate which comprises crystallizing dasatinib monohydrate from a solution of dasatinib in a solvent mixture of dimethyl sulfoxide and water.
  • Dasatinib used as non-solvated, solvated, hydrated forms as starting material of the invention may be obtained from known procedures.
  • the solvates of the present invention are useful intermediates for obtaining pure dasatinib.
  • the solvates and novel form of dasatinib of the present invention can be used to obtain known polymorphs of dasatinib.
  • composition comprising crystalline dasatinib form I.
  • the pharmaceutical dosage form may preferably be in solid dosage form.
  • Figure 1 is an X-ray powder diffraction pattern of dasatinib dimethylformamide solvate.
  • Figure 2 is an X-ray powder diffraction pattern of dasatinib dimethyl sulfoxide solvate.
  • Figure 3 is an X-ray powder diffraction pattern of dasatinib toluene solvate.
  • Figure 4 is an X-ray powder diffraction pattern of dasatinib isopropyl acetate solvate.
  • Figure 5 is an X-ray powder diffraction pattern of crystalline dasatinib form I.
  • X-ray powder diffraction spectrum was measured on a bruker axs D8 advance X-ray powder diffractometer having a copper-k ⁇ radiation. Approximately 1 gm of sample was gently flattened on a sample holder and scanned from 2 to 50 degrees two-theta, at 0.03 degrees two-theta per step and a step time of 0.5 seconds. The sample was simply placed on the sample holder. The sample was rotated at 30 rpm at a voltage 40KV and 35 mA.
  • Dasatinib (5 gm) obtained according to reference example was dissolved in ethyl acetate (300 ml) at 25 0 C and heated to reflux temperature. To the solution was added methanol (100 ml) and stirred for 30 minutes at reflux temperature to form clear solution. The solution was slowly cooled to room temperature and then cooled to O 0 C, stirred for 1 hour at O 0 C. The solid was collected by filtration and the solid was washed with mixture of ethyl acetate and methanol (20 ml, 3:1), and then dried the solid at 50 0 C under vacuum to obtain 3.5 gm of crystalline dasatinib form I.
  • Dasatinib (5 gm, HPLC purity: 99.2%) was dissolved in acetone (100 ml) and methanol (250 ml) and heated to reflux temperature, stirred for 30 minutes at reflux temperature to form clear solution. The solution was cooled to room temperature and then cooled to 20 0 C, stirred for 1 hour at 20 0 C. The solid was collected by filtration and the solid was washed with mixture of acetone (10 ml) and methanol (25 ml), and then dried the solid at 50 0 C under vacuum to obtain 4 gm of crystalline dasatinib form I (HPLC purity: 99.85%).
  • Dasatinib (5 gm, HPLC purity: 99.2%) was dissolved in dimethylformamide (25 ml) at 25 0 C and heated to 65 0 C to form clear solution. To the solution was slowly added acetone (50 ml) at 65 0 C and stirred for 1 hour at 65 0 C. The solution was slowly cooled to 25 0 C and stirred for 1 hour at 25 0 C. The contents are filtered and the solid obtained was washed with mixture of dimethylformamide and acetone (15 ml, 1:2), and then dried the solid at 50 0 C under vacuum to obtain 4 gm of dasatinib dimethylformamide solvate (HPLC purity: 99.94%).
  • Dasatinib (5 gm) was dissolved in dimethylformamide (25 ml) at 25 0 C and heated to 65 0 C to form clear solution. Ethyl acetate (50 ml) was added slowly to the solution at 65 0 C and stirred for 1 hour at 65 0 C. The solution was slowly cooled to 25 0 C, stirred for 1 hour at 25 0 C and filtered. The solid obtained was washed with mixture of dimethylformamide and ethyl acetate (30 ml, 1:2), and then dried the solid at 50 0 C under vacuum to obtain 4 gm of dasatinib dimethylformamide solvate.
  • Dasatinib (5 gm, HPLC purity: 99.2%) was dissolved in dimethylformamide (25 ml) and heated to 65 0 C to form a clear solution. The solution was cooled to 25 0 C and then cooled to 5 0 C, stirred for 4 hour at 5 0 C. The solid was collected by filtration and the solid was washed with chilled dimethylformamide (10 ml), and then dried the solid at 50 0 C under vacuum to obtain 4 gm of dasatinib dimethylformamide solvate (HPLC purity: 99.9%).
  • Dasatinib (5 gm, HPLC purity: 99.2%) was dissolved in dimethylformamide (25 ml) and heated to 65 0 C to form a clear solution. Water (50 ml) was added slowly to the solution at 65 0 C and stirred for 1 hour at 65 0 C. The solution was cooled to 25 0 C and stirred for 30 minutes at 25 0 C. The solid was collected by filtration and the solid was washed with mixture of dimethylformamide and water (15 ml, 1 :2), and then dried the solid at 50 0 C under vacuum to obtain 4.7 gm of dasatinib dimethylformamide solvate (HPLC purity: 99.93%).
  • Dasatinib dimethylformamide solvate (4.7 gm) obtained as in example 6 was dissolved in water (50 ml) and heated to 75 0 C, stirred for 4 hours at 75 0 C. The solution was cooled to 25 0 C, stirred for 30 minutes at 25 0 C and filtered. The solid obtained was washed with water (15 ml), and then dried at 50 0 C under vacuum to obtain 4.7 gm of dasatinib monohydrate.
  • Dasatinib (20 gm) was dissolved in dimethyl sulfoxide (100 ml) at 25 0 C and heated to 65 0 C to form clear solution. To the solution was slowly added water (200 ml) at 65 0 C and stirred for 1 hour at 65 0 C. The solution was slowly cooled to 25 0 C and stirred for 30 minutes at 25 0 C. The solid was collected by filtration and the solid was washed with mixture of dimethyl sulfoxide and water (30 ml, 1 :2), and then dried the solid at 50 0 C under vacuum to obtain 19.5 gm of dasatinib monohydrate.
  • Dasatinib (5 gm) was dissolved in isopropyl acetate (65 ml) and heated to 80 0 C, stirred for 1 hour at 80 0 C to form a clear solution. The solution was cooled to 25 0 C, stirred for 1 hour at 25 0 C and filtered. The solid obtained was washed with isopropyl acetate (15 ml) to obtain 5 gm of dasatinib isopropyl acetate solvate.
  • Dasatinib (6 gm) was dissolved in toluene (100 ml) and heated to reflux temperature, stirred for 2 hours at reflux temperature to form a clear solution. The solution was slowly cooled to 25 0 C. The contents are filtered and the solid obtained was washed with toluene (20 ml) to obtain 5.5 gm of dasatinib toluene solvate.
  • Dasatinib (5 gm) was dissolved in dimethyl sulfoxide (20 ml) at 25 0 C and heated to 65 0 C. To the solution was slowly added ethyl acetate (200 ml) at 65 0 C and the solution was slowly cooled to O 0 C, stirred for 2 hours at O 0 C. The solid was collected by filtration and the solid was washed with mixture of dimethyl sulfoxide and ethyl acetate (55 ml, 1 :10), and then dried the solid at 50 0 C under vacuum to obtain 4 gm of dasatinib dimethyl sulfoxide solvate.

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

The present invention provides a novel crystalline form I of dasatinib, process for its preparation and to pharmaceutical composition containing it. The present invention also provides dasatinib dimethylformamide solvate, dasatinib dimethyl sulfoxide solvate, dasatinib toluene solvate and dasatinib isopropyl acetate solvate, processes for its preparation. The present invention further provides a process for preparation of crystalline dasatinib monohydrate.

Description

POLYMORPHS OF DASATINIB
FIELD OF THE INVENTION
The present invention relates to novel polymorphs of dasatinib, processes for its preparation and to pharmaceutical compositions containing it.
BACKGROUND OF THE INVENTION
Dasatinib are antineoplastic agents, which were disclosed in WO Patent Publication No. 00/62778 and U.S. Patent No. 6,596,746. Dasatinib, chemically N-(2-chloro-6-methylphenyl)-2-[[6-[4-(2-hydroxyethyl)-1-piperazinyl]-2-methyl-4- pyrimidinyl]amino]-5-thiazolecarboxamide, is represented by the following structure:
Figure imgf000002_0001
Polymorphism is defined as "the ability of a substance to exist as two or more crystalline phases that have different arrangement and /or conformations of the molecules in the crystal Lattice. Thus, in the strict sense, polymorphs are different crystalline forms of the same pure substance in which the molecules have different arrangements and / or different configurations of the molecules". Different polymorphs may differ in their physical properties such as melting point, solubility, X-ray diffraction patterns, etc. Although those differences disappear once the compound is dissolved, they can appreciably influence pharmaceutically relevant properties of the solid form, such as handling properties, dissolution rate and stability. Such properties can significantly influence the processing, shelf life, and commercial acceptance of a polymorph. It is therefore important to investigate all solid forms of a drug, including all polymorphic forms, and to determine the stability, dissolution and flow properties of each polymorphic form. Polymorphic forms of a compound can be distinguished in the laboratory by analytical methods such as X-ray diffraction (XRD), Differential Scanning Calorimetry (DSC) and Infrared spectrometry (IR).
Solvent medium and mode of crystallization play very important role in obtaining a crystalline form over the other. Dasatinib can exist in different polymorphic forms, which differ from each other in terms of stability, physical properties, spectral data and methods of preparation.
U.S. Patent Application No. 2005/0215795 A1 (herein after referred to as the 795 patent application) described five crystalline forms of dasatinib (monohydrate, butanol solvate, ethanol solvate, neat form (N-6) and neat form (T1H1-7)), characterized by powder X-ray diffraction (P-XRD) pattern.
According to the '795 patent application, dasatinib monohydrate is characterized by an X-ray powder diffraction pattern having peaks expressed as 2Θ at approximately 18.0, 18.4, 19.2, 19.6, 21.2, 24.5, 25.9 and 28.0 ± 0.2 degrees. As per the process exemplified in the '795 patent application, dasatinb monohydrate can be obtained in dasatinib, by heating and dissolving the dasatinib in an ethanol and water mixture. Crystallizing the monohydrate from the ethanol and water mixture and cooled to get dasatinib monohydrate.
According to the '795 patent application, dasatinib crystalline butanol solvate is characterized by an X-ray powder diffraction pattern having peaks expressed as 2Θ at approximately 5.9, 12.0, 13.0, 17.7, 24.1 and 24.6 ± 0.2 degrees.
According to the 795 patent application, dasatinib crystalline ethanol solvate is characterized by an X-ray powder diffraction pattern having peaks expressed as 2Θ at approximately 5.8, 11.3, 15.8, 17.2, 19.5, 24.1, 25.3 and 26.2 ± 0.2 degrees.
According to the 795 patent application, dasatinib crystalline neat form (N-6) is characterized by an X-ray powder diffraction pattern having peaks expressed as 2Θ at approximately 6.8, 11.1, 12.3, 13.2, 13.7, 16.7, 21.0, 24.3 and 24.8 ± 0.2 degrees.
According to the 795 patent application, dasatinib crystalline neat form (T1H1-7) is characterized by an X-ray powder diffraction pattern having peaks expressed as 2Θ at approximately 8.0, 9.7, 11.2, 13.3, 17.5, 18.9, 21.0 and 22.0 ± 0.2 degrees.
U.S. Patent application No. 2006/0094728 disclosed ethanolate form (T1E2-1) of dasatinib, characterized by an X-ray powder diffraction pattern having peaks expressed as 2Θ at approximately 7.2, 12.0, 12.8, 18.0, 19.3 and 25.2 ± 0.2 degrees. We have discovered novel crystalline form of dasatinib, dasatinib dimethylformamide solvate, dasatinib dimethyl sulfoxide solvate, dasatinib toluene solvate and dasatinib isopropyl acetate solvate.
Another object of the present invention is to provide process for preparing the novel crystalline form of dasatinib, dasatinib dimethylformamide solvate, dasatinib dimethyl sulfoxide solvate, dasatinib toluene solvate, dasatinib isopropyl acetate solvate and known crystalline dasatinib monohydrate.
Still another object of the present invention is to provide pharmaceutical compositions containing the novel crystalline form of dasatinib.
DETAILED DESCRIPTION OF THE INVENTION
According to one aspect of the present invention there is provided dasatinib dimethyl formamide solvate, characterized by peaks in the powder x- ray diffraction spectrum having 2Θ angle positions at about 5.7, 11.5, 14.5, 17.3 and 25.1 ± 0.2 degrees. The powdered x-ray diffractogram (PXRD) of dasatinib dimethylformamide solvate is shown in figure 1.
According to another aspect of the present invention there is provided a process for preparing dasatinib dimethylformamide solvate which comprises crystallizing dasatinib dimethylformamide solvate from a solution of dasatinib in N,N-dimethylformamide solvent.
According to the invention, N,N-dimethylformamide may alone be present as solvent in the solution or N,N-dimethylformamide in combination with water or any other solvent or solvents may be present. For example, N1N- dimethylformamide in combination with ethyl acetate or acetone may be present in the solution.
According to another aspect of the present invention there is provided dasatinib dimethyl sulfoxide solvate, characterized by peaks in the powder x-ray diffraction spectrum having 2Θ angle positions at about 11.1, 15.1, 17.8, 19.0, 23.4 and 24.3 ± 0.2 degrees. The powdered x-ray diffractogram (PXRD) of dasatinib dimethyl sulfoxide solvate is shown in figure 2.
According to another aspect of the present invention there is provided a process for preparing dasatinib dimethyl sulfoxide solvate which comprises crystallizing dasatinib dimethyl sulfoxide solvate from a solution of dasatinib in a solvent mixture comprising dimethyl sulfoxide and ethyl acetate. According to another aspect of the present invention there is provided dasatinib toluene solvate, characterized by peaks in the powder x-ray diffraction spectrum having 2Θ angle positions at about 5.8, 11.8, 15.3, 21.6 and 24.6 ± 0.2 degrees. The powdered x-ray diffractogram (PXRD) of dasatinib toluene solvate is shown in figure 3.
According to another aspect of the present invention there is provided a process for preparing dasatinib toluene solvate which comprises crystallizing dasatinib toluene solvate from a solution of dasatinib in toluene.
According to another aspect of the present invention there is provided dasatinib isopropyl acetate solvate, characterized by peaks in the powder x-ray diffraction spectrum having 2Θ angle positions at about 5.7, 6.0, 6.7, 12.2, 13.1, 17.1 and 21.8± 0.2 degrees. The powdered x-ray diffractogram (PXRD) of dasatinib isopropyl acetate solvate is shown in figure 4.
According to another aspect of the present invention there is provided a process for preparing dasatinib isopropyl acetate solvate which comprises crystallizing dasatinib isopropyl acetate solvate from a solution of dasatinib in isopropyl acetate.
According to another aspect of the present invention there is provided a novel crystalline form of dasatinib. The crystalline form designated as dasatinib form I, characterized by peaks in the powder x-ray diffraction spectrum having 2Θ angle positions at about 7.1, 11.9, 12.2, 14.3, 16.4, 16.7, 19.0 and 24.1 ± 0.2 degrees. The powdered x-ray diffractogram (PXRD) of crystalline dasatinib form I is shown in figure 5.
The crystalline dasatinib form I may be identified and differentiated from the known polymorphs by its characteristic PXRD pattern. Thus, for example, a peak at 14.3 ± 0.2 degrees 2Θ is present in the PXRD of the crystalline dasatinib form I of the present invention, but is absent in the PXRD of the dasatinib crystalline neat form (N-6) disclosed in the US Patent Application No. 2005/0215795 Al
According to another aspect of the present invention there is provided a process for preparation of crystalline dasatinib form I which comprises crystallizing dasatinib form I from a solution of dasatinib in a solvent mixture of ethyl acetate and methanol, or acetone and methanol. According to another aspect of the present invention there is provided a process for preparation of crystalline dasatinib monohydrate which comprises crystallizing dasatinib monohydrate from a solution of dasatinib dimethylformamide solvate in water.
According to another aspect of the present invention there is provided a process for preparation of crystalline dasatinib monohydrate which comprises crystallizing dasatinib monohydrate from a solution of dasatinib in a solvent mixture of dimethyl sulfoxide and water.
Dasatinib used as non-solvated, solvated, hydrated forms as starting material of the invention may be obtained from known procedures.
The solvates of the present invention are useful intermediates for obtaining pure dasatinib. The solvates and novel form of dasatinib of the present invention can be used to obtain known polymorphs of dasatinib.
According to another aspect of the present invention there is provided a pharmaceutical composition comprising crystalline dasatinib form I.
The pharmaceutical dosage form may preferably be in solid dosage form.
BRIEF DESCRIPTION OF THE DRAWINGS
Figure 1 is an X-ray powder diffraction pattern of dasatinib dimethylformamide solvate.
Figure 2 is an X-ray powder diffraction pattern of dasatinib dimethyl sulfoxide solvate.
Figure 3 is an X-ray powder diffraction pattern of dasatinib toluene solvate.
Figure 4 is an X-ray powder diffraction pattern of dasatinib isopropyl acetate solvate.
Figure 5 is an X-ray powder diffraction pattern of crystalline dasatinib form I.
X-ray powder diffraction spectrum was measured on a bruker axs D8 advance X-ray powder diffractometer having a copper-kα radiation. Approximately 1 gm of sample was gently flattened on a sample holder and scanned from 2 to 50 degrees two-theta, at 0.03 degrees two-theta per step and a step time of 0.5 seconds. The sample was simply placed on the sample holder. The sample was rotated at 30 rpm at a voltage 40KV and 35 mA.
The following examples are given for the purpose of illustrating the present invention and should not be considered as limitation on the scope or spirit of the invention.
Reference Example
2-(6-Cholro-2-methylpyrimidin-4-yl-amino)-N-(2-chloro-6-methylphenyl) thiazole-5-carboxamide (15 gm) was added to 1-(2-hydroxyethyl)piperazine at 250C and heated to 850C, stirred for 2 hours 30 minutes at 850C. To the solution was added water (500 ml) at 800C and slowly cooled to 250C, stirred for 1 hour at 250C. The solid was collected by filtration and the solid was washed with water (50 ml), and then dried the solid at 550C under vacuum to obtain 15 gm of dasatinib.
Example 1
Dasatinib (5 gm) obtained according to reference example was dissolved in ethyl acetate (300 ml) at 250C and heated to reflux temperature. To the solution was added methanol (100 ml) and stirred for 30 minutes at reflux temperature to form clear solution. The solution was slowly cooled to room temperature and then cooled to O0C, stirred for 1 hour at O0C. The solid was collected by filtration and the solid was washed with mixture of ethyl acetate and methanol (20 ml, 3:1), and then dried the solid at 500C under vacuum to obtain 3.5 gm of crystalline dasatinib form I.
Example 2
Dasatinib (5 gm, HPLC purity: 99.2%) was dissolved in acetone (100 ml) and methanol (250 ml) and heated to reflux temperature, stirred for 30 minutes at reflux temperature to form clear solution. The solution was cooled to room temperature and then cooled to 200C, stirred for 1 hour at 200C. The solid was collected by filtration and the solid was washed with mixture of acetone (10 ml) and methanol (25 ml), and then dried the solid at 500C under vacuum to obtain 4 gm of crystalline dasatinib form I (HPLC purity: 99.85%).
Example 3
Dasatinib (5 gm, HPLC purity: 99.2%) was dissolved in dimethylformamide (25 ml) at 250C and heated to 650C to form clear solution. To the solution was slowly added acetone (50 ml) at 650C and stirred for 1 hour at 650C. The solution was slowly cooled to 250C and stirred for 1 hour at 250C. The contents are filtered and the solid obtained was washed with mixture of dimethylformamide and acetone (15 ml, 1:2), and then dried the solid at 500C under vacuum to obtain 4 gm of dasatinib dimethylformamide solvate (HPLC purity: 99.94%).
Example 4
Dasatinib (5 gm) was dissolved in dimethylformamide (25 ml) at 250C and heated to 650C to form clear solution. Ethyl acetate (50 ml) was added slowly to the solution at 650C and stirred for 1 hour at 650C. The solution was slowly cooled to 250C, stirred for 1 hour at 250C and filtered. The solid obtained was washed with mixture of dimethylformamide and ethyl acetate (30 ml, 1:2), and then dried the solid at 500C under vacuum to obtain 4 gm of dasatinib dimethylformamide solvate.
Example 5
Dasatinib (5 gm, HPLC purity: 99.2%) was dissolved in dimethylformamide (25 ml) and heated to 650C to form a clear solution. The solution was cooled to 250C and then cooled to 50C, stirred for 4 hour at 50C. The solid was collected by filtration and the solid was washed with chilled dimethylformamide (10 ml), and then dried the solid at 500C under vacuum to obtain 4 gm of dasatinib dimethylformamide solvate (HPLC purity: 99.9%).
Example 6
Dasatinib (5 gm, HPLC purity: 99.2%) was dissolved in dimethylformamide (25 ml) and heated to 650C to form a clear solution. Water (50 ml) was added slowly to the solution at 650C and stirred for 1 hour at 650C. The solution was cooled to 250C and stirred for 30 minutes at 250C. The solid was collected by filtration and the solid was washed with mixture of dimethylformamide and water (15 ml, 1 :2), and then dried the solid at 500C under vacuum to obtain 4.7 gm of dasatinib dimethylformamide solvate (HPLC purity: 99.93%).
Example 7
Dasatinib dimethylformamide solvate (4.7 gm) obtained as in example 6 was dissolved in water (50 ml) and heated to 750C, stirred for 4 hours at 750C. The solution was cooled to 250C, stirred for 30 minutes at 250C and filtered. The solid obtained was washed with water (15 ml), and then dried at 500C under vacuum to obtain 4.7 gm of dasatinib monohydrate.
Example 8
Dasatinib (20 gm) was dissolved in dimethyl sulfoxide (100 ml) at 250C and heated to 650C to form clear solution. To the solution was slowly added water (200 ml) at 650C and stirred for 1 hour at 650C. The solution was slowly cooled to 250C and stirred for 30 minutes at 250C. The solid was collected by filtration and the solid was washed with mixture of dimethyl sulfoxide and water (30 ml, 1 :2), and then dried the solid at 500C under vacuum to obtain 19.5 gm of dasatinib monohydrate.
Example 9
Dasatinib (5 gm) was dissolved in isopropyl acetate (65 ml) and heated to 800C, stirred for 1 hour at 800C to form a clear solution. The solution was cooled to 250C, stirred for 1 hour at 250C and filtered. The solid obtained was washed with isopropyl acetate (15 ml) to obtain 5 gm of dasatinib isopropyl acetate solvate.
Example 10
Dasatinib (6 gm) was dissolved in toluene (100 ml) and heated to reflux temperature, stirred for 2 hours at reflux temperature to form a clear solution. The solution was slowly cooled to 250C. The contents are filtered and the solid obtained was washed with toluene (20 ml) to obtain 5.5 gm of dasatinib toluene solvate.
Example 11
Dasatinib (5 gm) was dissolved in dimethyl sulfoxide (20 ml) at 250C and heated to 650C. To the solution was slowly added ethyl acetate (200 ml) at 650C and the solution was slowly cooled to O0C, stirred for 2 hours at O0C. The solid was collected by filtration and the solid was washed with mixture of dimethyl sulfoxide and ethyl acetate (55 ml, 1 :10), and then dried the solid at 500C under vacuum to obtain 4 gm of dasatinib dimethyl sulfoxide solvate.

Claims

We claim:
1. A dasatinib dimethylformamide solvate, characterized by an X-ray powder diffractogram having peaks expressed as 2Θ angle positions at about 5.7, 11.5, 14.5, 17.3 and 25.1 + 0.2 degrees.
2. A process for the preparation of dasatinib dimethylformamide solvate as defined in claim 1 , which comprises crystallizing dasatinib dimethylformamide solvate from a solution of dasatinib in N1N- dimethylformamide solvent.
3. The process as claimed in claim 2, wherein the N,N-dimethylformamide in combination with water or any other solvent or solvents.
4. The process as claimed in claim 3, wherein the solvent used in the process is ethyl acetate or acetone.
5. A dasatinib dimethyl sulfoxide solvate, characterized by an X-ray powder diffractogram having peaks expressed as 2Θ angle positions at about 11.1, 15.1 , 17.8, 19.0, 23.4 and 24.3 ± 0.2 degrees.
6. A process for the preparation of the dasatinib dimethyl sulfoxide solvate as defined in claim 5, which comprises crystallizing dasatinib dimethyl sulfoxide solvate from a solution of dasatinib in a solvent mixture comprising dimethyl sulfoxide and ethyl acetate.
7. A dasatinib toluene solvate, characterized by an X-ray powder diffractogram having peaks expressed as 2Θ angle positions at about 5.8, 11.8, 15.3, 21.6 and 24.6 ± 0.2 degrees.
8. A process for the preparation of the dasatinib toluene solvate as defined in claim 7, which comprises crystallizing dasatinib toluene solvate from a solution of dasatinib in toluene.
9. A dasatinib isopropyl acetate solvate, characterized by an X-ray powder diffractogram having peaks expressed as 2Θ angle positions at about 5.7, 6.0, 6.7, 12.2, 13.1, 17.1 and 21.8 ± 0.2 degrees.
10. A process for the preparation of the dasatinib isopropyl acetate as defined in claim 9, which comprises crystallizing dasatinib isopropyl acetate solvate from a solution of dasatinib in isopropyl acetate.
11. A crystalline dasatinib form I, characterized by an X-ray powder diffractogram having peaks expressed as 2Θ angle positions at about 7.1, 11.9, 12.2, 14.3, 16.4, 19.0 and 24.1 ± 0.2 degrees.
12. A process for the preparation of the crystalline dasatinib form I as claimed in claim 11 , which comprises crystallizing dasatinib form I from a solution of dasatinib in a solvent mixture of ethyl acetate and methanol, or acetone and methanol.
13. A process for the preparation of the crystalline dasatinib monohydrate which comprises which comprises crystallizing dasatinib monohydrate from a solution of dasatinib dimethylformamide solvate in water.
14. A process for the preparation of the crystalline dasatinib monohydrate which comprises crystallizing dasatinib monohydrate from a solution of dasatinib in a solvent mixture of dimethyl sulfoxide and water.
15. A pharmaceutical composition comprising crystalline dasatinib form I of claim 11 and a pharmaceutically acceptable excipient.
16. The pharmaceutical composition as claimed in claim 15, wherein the pharmaceutical composition of crystalline dasatinib form I is a solid dosage form.
PCT/IN2008/000822 2008-12-08 2008-12-08 Polymorphs of dasatinib WO2010067374A2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
PCT/IN2008/000822 WO2010067374A2 (en) 2008-12-08 2008-12-08 Polymorphs of dasatinib

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/IN2008/000822 WO2010067374A2 (en) 2008-12-08 2008-12-08 Polymorphs of dasatinib

Publications (2)

Publication Number Publication Date
WO2010067374A2 true WO2010067374A2 (en) 2010-06-17
WO2010067374A3 WO2010067374A3 (en) 2011-05-26

Family

ID=42243139

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IN2008/000822 WO2010067374A2 (en) 2008-12-08 2008-12-08 Polymorphs of dasatinib

Country Status (1)

Country Link
WO (1) WO2010067374A2 (en)

Cited By (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102030745A (en) * 2010-11-26 2011-04-27 江苏先声药物研究有限公司 Dasatinib solvate and preparation method thereof
CN102086195A (en) * 2011-01-28 2011-06-08 南京卡文迪许生物工程技术有限公司 Dasatinib polymorphic substance as well as preparation method and medicinal composition thereof
WO2012014149A1 (en) 2010-07-30 2012-02-02 Ranbaxy Laboratories Limited N-methylformamide solvate of dasatinib
US20120309968A1 (en) * 2010-02-08 2012-12-06 Nan Jing Cavendish Bio-Engineering Technology Co., Ltd. Polymorphs of dasatinib, preparation methods and pharmaceutical compositions thereof
CN102898424A (en) * 2011-07-29 2013-01-30 江苏奥赛康药业股份有限公司 Novel polymorphs of dasatinib, and preparation method thereof
CN103059013A (en) * 2011-10-18 2013-04-24 北京本草天源药物研究院 New crystal of Dasatinib monohydrate and preparation method thereof
WO2013065063A1 (en) 2011-11-03 2013-05-10 Cadila Healthcare Limited Anhydrous form of dasatinib, process for its preparation and its use
WO2013186726A3 (en) * 2012-06-15 2014-02-20 Basf Se Multicomponent crystals comprising dasatinib and selected cocrystal formers
CN103833745A (en) * 2012-11-22 2014-06-04 上海博悦生物科技有限公司 New polycrystalline substance alpha form of dasatinib monohydrate and preparation method thereof
WO2014086326A1 (en) 2012-12-06 2014-06-12 Zentiva, K.S. A method for the preparation and purification of new and known polymorphs and solvates of dasatinib
CN103880833A (en) * 2012-12-19 2014-06-25 北京本草天源药物研究院 Novel crystal form of dasatinib monohydrate, and preparation method and pharmaceutical composition thereof
US9168226B1 (en) 2015-08-07 2015-10-27 David Wong Injectable particle
CN104997737A (en) * 2015-08-05 2015-10-28 青岛蓝盛洋医药生物科技有限责任公司 Composition dry suspension of medicine dasatinib tablet for treating leukemia
CN105055327A (en) * 2015-07-30 2015-11-18 青岛蓝盛洋医药生物科技有限责任公司 Dasatinib composite granules capable of treating leukaemia
CN105055367A (en) * 2015-08-18 2015-11-18 青岛蓝盛洋医药生物科技有限责任公司 SprycelTM composition capsule medicine for treating leukemia
WO2016001025A1 (en) 2014-06-30 2016-01-07 Basf Se Multicomponent crystals of dasatinib with menthol or vanillin
US9556164B2 (en) 2013-07-25 2017-01-31 Basf Se Salts of Dasatinib in crystalline form
WO2017108605A1 (en) 2015-12-22 2017-06-29 Synthon B.V. Pharmaceutical composition comprising amorphous dasatinib
CN107033137A (en) * 2016-02-03 2017-08-11 正大天晴药业集团股份有限公司 A kind of crystal formation of Dasatinib and preparation method thereof
US9884857B2 (en) 2013-07-25 2018-02-06 Basf Se Salts of dasatinib in amorphous form
WO2019209908A1 (en) 2018-04-25 2019-10-31 Johnson Matthey Public Limited Company Crystalline forms of dasatinib
US10799459B1 (en) 2019-05-17 2020-10-13 Xspray Microparticles Ab Rapidly disintegrating solid oral dosage forms containing dasatinib
US10940149B1 (en) 2018-06-15 2021-03-09 Handa Oncology, Llc Kinase inhibitor salts and compositions thereof
US11059813B2 (en) 2017-07-07 2021-07-13 Biocon Limited Polymorphic forms of Dasatinib

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005077945A2 (en) * 2004-02-06 2005-08-25 Bristol-Myers Squibb Company Process for preparing 2-aminothiazole-5-aromatic carboxamides as kinase inhibitors
WO2009053854A2 (en) * 2007-10-23 2009-04-30 Teva Pharmaceutical Industries Ltd. Polymorphs of dasatinib and process for preparation thereof
WO2010062715A2 (en) * 2008-11-03 2010-06-03 Teva Pharmaceutical Industries Ltd. Polymorphs of dasatinib and process for preparation thereof

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005077945A2 (en) * 2004-02-06 2005-08-25 Bristol-Myers Squibb Company Process for preparing 2-aminothiazole-5-aromatic carboxamides as kinase inhibitors
WO2009053854A2 (en) * 2007-10-23 2009-04-30 Teva Pharmaceutical Industries Ltd. Polymorphs of dasatinib and process for preparation thereof
WO2010062715A2 (en) * 2008-11-03 2010-06-03 Teva Pharmaceutical Industries Ltd. Polymorphs of dasatinib and process for preparation thereof

Cited By (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20120309968A1 (en) * 2010-02-08 2012-12-06 Nan Jing Cavendish Bio-Engineering Technology Co., Ltd. Polymorphs of dasatinib, preparation methods and pharmaceutical compositions thereof
US8884013B2 (en) * 2010-02-08 2014-11-11 Nan Jing Cavendish Bio-Engineering Technology Co., Ltd. Polymorphs of Dasatinib, preparation methods and pharmaceutical compositions thereof
WO2012014149A1 (en) 2010-07-30 2012-02-02 Ranbaxy Laboratories Limited N-methylformamide solvate of dasatinib
CN102030745A (en) * 2010-11-26 2011-04-27 江苏先声药物研究有限公司 Dasatinib solvate and preparation method thereof
CN102086195A (en) * 2011-01-28 2011-06-08 南京卡文迪许生物工程技术有限公司 Dasatinib polymorphic substance as well as preparation method and medicinal composition thereof
CN102898424A (en) * 2011-07-29 2013-01-30 江苏奥赛康药业股份有限公司 Novel polymorphs of dasatinib, and preparation method thereof
CN103059013A (en) * 2011-10-18 2013-04-24 北京本草天源药物研究院 New crystal of Dasatinib monohydrate and preparation method thereof
WO2013065063A1 (en) 2011-11-03 2013-05-10 Cadila Healthcare Limited Anhydrous form of dasatinib, process for its preparation and its use
WO2013186726A3 (en) * 2012-06-15 2014-02-20 Basf Se Multicomponent crystals comprising dasatinib and selected cocrystal formers
US9340536B2 (en) 2012-06-15 2016-05-17 Basf Se Multicomponent crystals comprising dasatinib and selected co-crystal formers
JP2015525227A (en) * 2012-06-15 2015-09-03 ビーエーエスエフ ソシエタス・ヨーロピアＢａｓｆ Ｓｅ Multi-component crystals comprising dasatinib and a selected co-crystal former
RU2650524C2 (en) * 2012-06-15 2018-04-16 Басф Се Multicomponent crystals comprising dasatinib and selected cocrystal formers
AU2013276138B2 (en) * 2012-06-15 2017-02-23 Basf Se Multicomponent crystals comprising Dasatinib and selected cocrystal formers
CN103833745A (en) * 2012-11-22 2014-06-04 上海博悦生物科技有限公司 New polycrystalline substance alpha form of dasatinib monohydrate and preparation method thereof
WO2014086326A1 (en) 2012-12-06 2014-06-12 Zentiva, K.S. A method for the preparation and purification of new and known polymorphs and solvates of dasatinib
CN103880833A (en) * 2012-12-19 2014-06-25 北京本草天源药物研究院 Novel crystal form of dasatinib monohydrate, and preparation method and pharmaceutical composition thereof
CN103880833B (en) * 2012-12-19 2018-04-06 北京本草天源药物研究院 New crystalline form of Dasatinib monohydrate and preparation method thereof and pharmaceutical composition
US9884857B2 (en) 2013-07-25 2018-02-06 Basf Se Salts of dasatinib in amorphous form
US9556164B2 (en) 2013-07-25 2017-01-31 Basf Se Salts of Dasatinib in crystalline form
WO2016001025A1 (en) 2014-06-30 2016-01-07 Basf Se Multicomponent crystals of dasatinib with menthol or vanillin
CN105055327A (en) * 2015-07-30 2015-11-18 青岛蓝盛洋医药生物科技有限责任公司 Dasatinib composite granules capable of treating leukaemia
CN104997737A (en) * 2015-08-05 2015-10-28 青岛蓝盛洋医药生物科技有限责任公司 Composition dry suspension of medicine dasatinib tablet for treating leukemia
US9168226B1 (en) 2015-08-07 2015-10-27 David Wong Injectable particle
CN105055367A (en) * 2015-08-18 2015-11-18 青岛蓝盛洋医药生物科技有限责任公司 SprycelTM composition capsule medicine for treating leukemia
WO2017108605A1 (en) 2015-12-22 2017-06-29 Synthon B.V. Pharmaceutical composition comprising amorphous dasatinib
CN107033137A (en) * 2016-02-03 2017-08-11 正大天晴药业集团股份有限公司 A kind of crystal formation of Dasatinib and preparation method thereof
US11059813B2 (en) 2017-07-07 2021-07-13 Biocon Limited Polymorphic forms of Dasatinib
WO2019209908A1 (en) 2018-04-25 2019-10-31 Johnson Matthey Public Limited Company Crystalline forms of dasatinib
US11440908B2 (en) 2018-04-25 2022-09-13 Johnson Matthey Public Limited Company Crystalline forms of dasatinib
US10940149B1 (en) 2018-06-15 2021-03-09 Handa Oncology, Llc Kinase inhibitor salts and compositions thereof
US11007195B2 (en) 2018-06-15 2021-05-18 Handa Oncology, Llc Kinase inhibitor salts, and compositions thereof
US11052088B2 (en) 2018-06-15 2021-07-06 Handa Oncology, Llc Kinase inhibitor salts, and compositions thereof
US11160805B2 (en) 2018-06-15 2021-11-02 Handa Onocology, Llc Kinase inhibitor salts and compositions thereof
US10874613B1 (en) 2019-05-17 2020-12-29 Xspray Pharma Ab Rapidly disintegrating solid oral dosage forms containing dasatinib
US10874614B1 (en) 2019-05-17 2020-12-29 Xspray Pharma Ab Rapidly disintegrating solid oral dosage forms containing dasatinib
US10894017B1 (en) 2019-05-17 2021-01-19 Xspray Pharma Ab Rapidly disintegrating solid oral dosage forms containing dasatinib
US10894018B1 (en) 2019-05-17 2021-01-19 Xspray Pharma Ab Rapidly disintegrating solid oral dosage forms containing dasatinib
US10869836B1 (en) 2019-05-17 2020-12-22 Xspray Pharma Ab Rapidly disintegrating solid oral dosage forms containing dasatinib
US10869837B1 (en) 2019-05-17 2020-12-22 Xspray Pharma Ab Rapidly disintegrating solid oral dosage forms containing dasatinib
US11344500B2 (en) 2019-05-17 2022-05-31 Xspray Pharma Ab Rapidly disintegrating solid oral dosage forms containing dasatinib
US10799459B1 (en) 2019-05-17 2020-10-13 Xspray Microparticles Ab Rapidly disintegrating solid oral dosage forms containing dasatinib
US11833249B2 (en) 2019-05-17 2023-12-05 Xspray Pharma Ab Rapidly disintegrating solid oral dosage forms containing dasatinib

Also Published As

Publication number Publication date
WO2010067374A3 (en) 2011-05-26

Similar Documents

Publication Publication Date Title
WO2010067374A2 (en) Polymorphs of dasatinib
JP5798101B2 (en) Of 4-methyl-N- [3- (4-methyl-imidazol-1-yl) -5-trifluoromethyl-phenyl] -3- (4-pyridin-3-yl-pyrimidin-2-ylamino) -benzamide Crystal form
EP2438062B1 (en) Process for the preparation of amorphous raltegravir potassium
ES2565521T5 (en) Dasatinib polymorphs and their preparation process
US8329740B2 (en) Polymorphs of sunitinib malate
WO2013046229A1 (en) Novel salts of alogliptin
WO2013065063A1 (en) Anhydrous form of dasatinib, process for its preparation and its use
AU2011284341A1 (en) N-Methylformamide solvate of dasatinib
WO2017098391A1 (en) Process for the preparation of dasatinib
US8962833B2 (en) Salts of raltegravir
US8445506B2 (en) Polymorphs of lopinavir
US8552036B2 (en) Polymorph of atazanavir sulfate
US20130190368A1 (en) Novel polymorphs of febuxostat
WO2010079498A2 (en) Novel polymorph of sorafenib tosylate
WO2014013511A2 (en) Rufinamide solid dispersion
US20150291574A1 (en) Novel polymorphs of azilsartan
WO2011016044A1 (en) Novel polymorphs of adefovir dipivoxil
WO2010146594A1 (en) Novel polymorphs of gemifloxacin mesylate

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 4350/CHENP/2009

Country of ref document: IN

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 08878693

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase in:

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 08878693

Country of ref document: EP

Kind code of ref document: A2